Tonix Announces First Participant Dosed In Phase 1 Investigator-Initiated Study To Evaluate Effect Of TNX-1900 On Trigeminal Nerve-Mediated Vasodilation Of Forehead Using Capsaicin As Well As Electrical Stimulation

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced that the first participant has been dosed in a Phase 1 investigator-initiated study evaluating TNX-1900, an intranasal potentiated oxytocin, for its effects on trigeminal nerve-mediated vasodilation. The study, led by Dr. Antoinette Maassen van den Brink, will assess the response of forehead skin blood flow to capsaicin and electrical stimulation in healthy female volunteers. TNX-1900 targets a pathway distinct from existing CGRP migraine treatments, potentially offering a new approach to managing craniofacial pain conditions such as migraine and trigeminal neuralgia.